Bavarian Nordic A/S (BAVA.VI)
Company Overview
Company Name
Bavarian Nordic A/S
Symbol
BAVA.VI
Exchange
Vienna
Daily Change
-0.24%
52 Week Change
-7.11%
52-Week Range
17.915 - 32.520 EUR
Market Cap
1.92B EUR
Sector
-
Industry
Biotechnology
Employees
1,738
Country
Denmark
Website
Business Summary
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Market Information
Currency
EUR
First Trade Date
12/22/2022
Regular Market Change
-0.0600 (-0.0024%)
Regular Market Volume
-
Average Daily Volume (3M)
7